Document is current
Any future updates will be listed below
-
Authors
Di Maio, Silvia
Zöscher, Peter
Weissensteiner, Hansi
Forer, Lukas
Schachtl-Riess, Johanna F.
Amstler, Stephan
Streiter, Gertraud
Pfurtscheller, Cathrin
Paulweber, Bernhard
Kronenberg, Florian
Coassin, Stefan
Schönherr, Sebastian https://orcid.org/0000-0001-5909-9226
-
Funding
Funding for this research was provided by:
Austrian Science Fund (P31458-B34, W-1253DK HOROS)
European Atherosclerosis Society (Research Grant 2018)
Dr. Legerlotz Foundation
- License Information
-
More Information
Article History
Received: 28 June 2023
Accepted: 18 June 2024
First Online: 26 June 2024
Declarations
:
: The samples of the KIV-variation dataset were drawn from Central-European individuals (SAPHIR study) previously screened for mutations in the KIV-2 region by ultra-deep targeted sequencing []. Informed consent was obtained from each participant and the analysis was carried out in accordance with the local ethics committee (Salzburg, Austria, EK Nr: 1074/2021).The UK Biobank study was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent prior to the enrolment. UKB received ethical approval from the North West Multi-Centre Research Ethics Committee (REC reference: 11/NW/0382).
: Not applicable.
: S.C. has obtained honoraria from Novartis AG (Basel, CH) and Silence Therapeutics PLC (London, UK) for <i>LPA</i> genetics consultancy. F.K. has received honoraria from Novartis AG, CRISPR Therapeutics, Silence Therapeutics, Roche, and Amgen for Lp(a) consultancy and fees for lectures. L.F. has obtained honoraria from Novartis AG (Basel, CH) for <i>LPA</i> genetics consultancy. All other authors declare that they have no competing interests.
